Martina Wiedau, MD
Neurology · Los Angeles, CANPI 1528086824
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,455 of the $49,531 with a category attached, or 71.6%. Tanabe Pharma America, Inc. accounts for 88.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $20,231 and has fallen 99.3% since, to $151 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $202.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tanabe Pharma America, Inc.$44K
- Amylyx Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Novartis$776
- Amgen$168
- plus $864 from 15 others
Across 45 payments — averaging $4613.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tanabe Pharma America, Inc.$96K
- Mitsubishi Tanabe Pharma Development America, Inc.$77K
- Mallinckrodt Enterprises LLC$28K
- Mallinckrodt Hospital Products Inc.$7K
What the payments were for
- Consulting fees$35,45572%
- Speaking & faculty fees$5,41911%
- Travel & lodging$3,5317%
- Food & beverage$5,09410%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tanabe Pharma America, Inc. | 50 | $43,901 |
| Amylyx Pharmaceuticals, Inc. | 4 | $1,405 |
| AbbVie(2 entities) | 54 | $1,277 |
| Teva Pharmaceuticals USA, Inc. | 54 | $1,139 |
| Novartis | 37 | $776 |
| Amgen | 6 | $168 |
| EMD Serono, Inc. | 7 | $139 |
| Lilly USA, LLC | 6 | $122 |
| Mallinckrodt Hospital Products Inc. | 3 | $88 |
| Biogen | 3 | $68 |
| UCB, Inc. | 2 | $59 |
| CSL Behring | 3 | $57 |
| EDW Pharma, Inc. | 2 | $51 |
| Acorda Therapeutics, Inc | 2 | $49 |
| Neurocrine Biosciences, Inc. | 3 | $48 |
| Avanir Pharmaceuticals, Inc. | 2 | $44 |
| Bausch Health US, LLC | 2 | $36 |
| Integra Lifesciences Corporation | 1 | $32 |
| Pfizer | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Assertio Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Radicava$39,581
- Radicava ORS$11,613
- RELYVRIO$1,350
- GILENYA$108
How this compares
$49,531 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 176 | $2,484,235 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 49 | $730,137 |
| BriviactBrivaracetam | 12 | $31,666 |
| Nurtec OdtRimegepant Sulfate | 22 | $29,020 |
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $24,024 |
| Emgality PenGalcanezumab-Gnlm | 23 | $16,973 |
| Riluzole | 67 | $13,613 |
| Memantine Hcl | 57 | $4,204 |
| Oxycodone Hcl | 14 | $3,909 |
| Gabapentin | 103 | $3,708 |
| Lacosamide | 14 | $2,546 |
| Sumatriptan Succinate | 50 | $1,539 |
| Primidone | 31 | $1,369 |
| Levetiracetam | 31 | $1,341 |
| Oxcarbazepine | 18 | $1,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $59 | $31,66612 claims |
| PfizerNurtec Odt | $29 | $29,02022 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $44 | $24,02416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.